140 related articles for article (PubMed ID: 15233228)
21. In vitro testing of new somatostatin analogs on pituitary tumor cells.
Zatelli MC; Ambrosio MR; Bondanelli M; degli Uberti EC
Mol Cell Endocrinol; 2008 May; 286(1-2):187-91. PubMed ID: 18243520
[TBL] [Abstract][Full Text] [Related]
22. [Somatostatin receptors--new diagnostic and therapeutic possibilities].
Pawlikowski M
Endokrynol Pol; 2005; 56(1):4-5. PubMed ID: 16335666
[No Abstract] [Full Text] [Related]
23. Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells.
Watt HL; Kharmate GD; Kumar U
Cell Signal; 2009 Mar; 21(3):428-39. PubMed ID: 19070659
[TBL] [Abstract][Full Text] [Related]
24. Editorial: somatostatin receptor-based scintigraphy and antitumor treatment--an expanding vista?
Jensen RT
J Clin Endocrinol Metab; 2000 Oct; 85(10):3507-8. PubMed ID: 11061490
[No Abstract] [Full Text] [Related]
25. [Modern approaches to estrogen-independent growth of breast tumor].
Krasil'nikov MA
Vopr Onkol; 2004; 50(4):399-405. PubMed ID: 15605761
[No Abstract] [Full Text] [Related]
26. Future clinical prospects in somatostatin/cortistatin/somatostatin receptor field.
Dalm VA; Hofland LJ; Lamberts SW
Mol Cell Endocrinol; 2008 May; 286(1-2):262-77. PubMed ID: 17942217
[TBL] [Abstract][Full Text] [Related]
27. Function and expression of somatostatin receptors of the endocrine pancreas.
Strowski MZ; Blake AD
Mol Cell Endocrinol; 2008 May; 286(1-2):169-79. PubMed ID: 18375050
[TBL] [Abstract][Full Text] [Related]
28. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
[TBL] [Abstract][Full Text] [Related]
29. Somatostatin-receptor mediated diagnosis and treatment in gastrointestinal neuroendocrine tumours (GEP-NET's).
Oberg K
Rocz Akad Med Bialymst; 2005; 50():62-8. PubMed ID: 16358941
[No Abstract] [Full Text] [Related]
30. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.
Siehler S; Nunn C; Zupanc GK; Hoyer D
Auton Autacoid Pharmacol; 2005 Jan; 25(1):1-16. PubMed ID: 15659149
[TBL] [Abstract][Full Text] [Related]
31. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
32. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro.
de Bruin C; Feelders RA; Waaijers AM; van Koetsveld PM; Sprij-Mooij DM; Lamberts SW; Hofland LJ
J Mol Endocrinol; 2009 Jan; 42(1):47-56. PubMed ID: 18852217
[TBL] [Abstract][Full Text] [Related]
33. Hormonal therapy for advanced breast cancer.
Rugo HS
Hematol Oncol Clin North Am; 2007 Apr; 21(2):273-91. PubMed ID: 17512449
[TBL] [Abstract][Full Text] [Related]
34. Conclusions: the future role of somatostatin analogs.
Lamberts SW
J Endocrinol Invest; 2003; 26(8 Suppl):134-5. PubMed ID: 15233230
[No Abstract] [Full Text] [Related]
35. Androgens and androgen receptors: a clinically neglected sector in breast cancer biology.
Moe RE; Anderson BO
J Surg Oncol; 2007 May; 95(6):437-9. PubMed ID: 17192921
[No Abstract] [Full Text] [Related]
36. RT-PCR and immunocytochemistry studies support the presence of somatostatin, cortistatin and somatostatin receptor subtypes in rat Kupffer cells.
Xidakis C; Mastrodimou N; Notas G; Renieri E; Kolios G; Kouroumalis E; Thermos K
Regul Pept; 2007 Oct; 143(1-3):76-82. PubMed ID: 17481746
[TBL] [Abstract][Full Text] [Related]
37. Dephosphorylation of cancer protein by tyrosine phosphatases in response to analogs of luteinizing hormone-releasing hormone and somatostatin.
Lee LT; Schally AV; Liebow C; Lee PP; Lee PH; Lee MT
Anticancer Res; 2008; 28(5A):2599-605. PubMed ID: 19035284
[TBL] [Abstract][Full Text] [Related]
38. New approaches to reverse resistance to hormonal therapy in human breast cancer.
Weinberg OK; Marquez-Garban DC; Pietras RJ
Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
[TBL] [Abstract][Full Text] [Related]
39. Positive somatostatin receptor imaging does not predict somatostatin analogue efficacy in tumor-induced osteomalacia.
Łebek-Szatańska A; Papierska L; Marcinowska-Suchowierska E; Nowak KM; Zgliczyński W; Misiorowski W
Pol Arch Intern Med; 2018 Sep; 128(9):554-555. PubMed ID: 30141426
[No Abstract] [Full Text] [Related]
40. Responsiveness to somatostatin analog treatment and potentials of novel somatostatin analog.
Hofland LJ
J Endocrinol Invest; 2003; 26(8 Suppl):8-13. PubMed ID: 15233204
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
